223 related articles for article (PubMed ID: 11016746)
1. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Di Bonito M; Rivellini F; Carteni G; De Lucia L; Maiorino L; D'Aniello R; Frezza P; Lapenta L; Comella G
Breast Cancer Res Treat; 2000 Jul; 62(2):87-97. PubMed ID: 11016746
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
3. Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
Frasci G; Comella P; Carreca I; DeCataldis G; Muci D; Brunetti C; Russo A; Palmeri S; D'Aniello R; Giordano R; D'Aiuto M; Comella G;
Oncology; 2005; 68(2-3):223-9. PubMed ID: 16015038
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
5. Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Botti G; Di Bonito M; De Rosa V; Iodice G; Rubulotta MR; Comella G;
Br J Cancer; 2006 Oct; 95(8):1005-12. PubMed ID: 17047649
[TBL] [Abstract][Full Text] [Related]
6. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.
Frasci G; Comella P; Rinaldo M; Iodice G; Di Bonito M; D'Aiuto M; Petrillo A; Lastoria S; Siani C; Comella G; D'Aiuto G
Ann Oncol; 2009 Jul; 20(7):1185-92. PubMed ID: 19218307
[TBL] [Abstract][Full Text] [Related]
7. A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Botti G; Di Bonito M; D'Aiuto M; Romano G; Rubulotta MR; Comella G
Ann Oncol; 2005 Aug; 16(8):1268-75. PubMed ID: 15937055
[TBL] [Abstract][Full Text] [Related]
8. Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Frasci G; D'Aiuto G; Comella P; D'Aiuto M; Di Bonito M; Ruffolo P; Iodice G; Petrillo A; Lastoria S; Oliviero P; Capasso I; Montella M; Siani C; Santangelo M; Vizioli L; Comella G;
Ann Oncol; 2010 Apr; 21(4):707-716. PubMed ID: 19815652
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
[TBL] [Abstract][Full Text] [Related]
10. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
[TBL] [Abstract][Full Text] [Related]
11. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
13. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study.
Frasci G; Nicolella G; Comella P; Carreca I; DeCataldis G; Muci D; Brunetti C; Natale M; Piantedosi F; Russo A; Palmeri S; Comella G; Panza N
Br J Cancer; 2001 May; 84(9):1166-71. PubMed ID: 11336465
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.
Nisticò C; Garufi C; Barni S; Frontini L; Gallà DA; Giannarelli D; Vaccaro A; D'Ottavio AM; Terzoli E
Ann Oncol; 1999 Aug; 10(8):937-42. PubMed ID: 10509155
[TBL] [Abstract][Full Text] [Related]
15. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.
Wasserheit C; Frazein A; Oratz R; Sorich J; Downey A; Hochster H; Chachoua A; Wernz J; Zeleniuch-Jacquotte A; Blum R; Speyer J
J Clin Oncol; 1996 Jul; 14(7):1993-9. PubMed ID: 8683229
[TBL] [Abstract][Full Text] [Related]
17. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Frasci G; D'Aiuto G; Thomas R; Comella P; Di Bonito M; Lapenta L; D'Aiuto M; Botti G; Vallone P; De Rosa V; D'Aniello R; Giordano R; Comella G
Oncology; 2005; 68(4-6):391-7. PubMed ID: 16020968
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study.
Papadimitriou CA; Moulopoulos LA; Vlahos G; Voulgaris Z; Kiosses E; Georgoulias N; Gika D; Diakomanolis E; Michalas S; Dimopoulos MA
Cancer; 2000 Oct; 89(7):1547-54. PubMed ID: 11013370
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
Ries F; Duhem C; Kleiber K; Dicato M
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
